The estimated Net Worth of Roman Yelensky is at least $1.25 Milion dollars as of 8 March 2021. Roman Yelensky owns over 50,724 units of Gritstone Bio Inc stock worth over $90,135 and over the last 6 years he sold GRTS stock worth over $221,000. In addition, he makes $943,054 as Executive Vice President a Chief Technology Officer at Gritstone Bio Inc.
Roman has made over 2 trades of the Gritstone Bio Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 50,724 units of GRTS stock worth $38,550 on 8 March 2021.
The largest trade he's ever made was exercising 50,724 units of Gritstone Bio Inc stock on 8 March 2021 worth over $38,550. On average, Roman trades about 10,121 units every 8 days since 2019. As of 8 March 2021 he still owns at least 183,948 units of Gritstone Bio Inc stock.
You can see the complete history of Roman Yelensky stock trades at the bottom of the page.
Dr. Roman Yelensky Ph.D. serves as Executive Vice President, Chief Technology Officer of the Company. Yelensky has served as our Executive Vice President, Chief Technology Officer since March 2017. He joined Gritstone at its inception in October 2015 as executive vice president of sequencing and bioinformatics. Prior to Gritstone, from July 2010 to September 2015, Dr. Yelensky served as vice president of biomarker and companion diagnostic development at Foundation Medicine. Prior to Foundation Medicine, Dr. Yelensky was a senior scientist in biomarker development at Novartis AG from April 2009 to July 2010. He received a B.A. in computer science from Cornell University, an M.S. in computer science from Stanford University and a Ph.D. in bioinformatics and integrative genomics from the Harvard-MIT Division of Health Sciences and Technology.
As the Executive Vice President a Chief Technology Officer of Gritstone Bio Inc, the total compensation of Roman Yelensky at Gritstone Bio Inc is $943,054. There are 4 executives at Gritstone Bio Inc getting paid more, with Andrew Allen having the highest compensation of $2,187,440.
Roman Yelensky is 41, he's been the Executive Vice President a Chief Technology Officer of Gritstone Bio Inc since 2017. There are 17 older and 1 younger executives at Gritstone Bio Inc. The oldest executive at Gritstone Bio Inc is Alan C. Mendelson J.D., 71, who is the Sec..
Roman's mailing address filed with the SEC is C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE, CA, 94608.
Over the last 6 years, insiders at Gritstone Bio Inc have traded over $277,077 worth of Gritstone Bio Inc stock and bought 2,026,375 units worth $15,022,790 . The most active insiders traders include Group, Llc Green Jeremy Red..., Peter Svennilson a Thomas Woiwode. On average, Gritstone Bio Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,654. The most recent stock trade was executed by Andrew R Allen on 15 May 2024, trading 24,263 units of GRTS stock currently worth $18,197.
gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.
Gritstone Bio Inc executives and other stock owners filed with the SEC include: